http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5503984-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6636b59c3149a23a6ae7feaa3984d05f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 1993-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09c73c524d7aaccd4f38cbca0ab924ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eea9fee44e4a68f3cd0af1480a90f750 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_431e6017a787d5aaa0af347eb6d0c344 |
| publicationDate | 1996-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5503984-A |
| titleOfInvention | Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein |
| abstract | A unique monoclonal antibody against P-glycoprotein. The monoclonal antibody is different than those previously described and has the surprising property of reacting to a soluble form of P-glycoprotein. The invention further includes a novel hybridoma cell line which produces the antibody. A preferred embodiment of the novel antibody has been designated F4 which is believed to react at or near an extracellular transmembrane loop of P-glycoprotein selected from the group consisting of the third and sixth extracellular loops. The invention further comprises a method for detecting the presence of P-glycoprotein comprising reacting a specimen containing P-glycoprotein with the novel monoclonal antibody and detecting the reaction to show that P-glycoprotein is present. The invention, in a preferred embodiment, comprises detecting the presence of drug resistant carcinoma cells, in the absence of biopsy, comprising removing extracellular fluids from a patient for use as a specimen, and determining the presence of P-glycoprotein in the specimen by reacting the specimen with the the novel monoclonal antibody to show that P-glycoprotein is present as an indicator of drug resistance. The extracellular fluid may be any suitable fluid which could contain P-glycoprotein as an indicator of drug resistance. Such fluids may for example be plasma, lymph excretions, and especially ascites taken from the area of a tumor site. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004166110-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6734192-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006068426-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2906533-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8808667-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010146650-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8241646-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004171636-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008046724-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101516394-B |
| priorityDate | 1993-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.